pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
fda press·May 12·1 min read
save

FDA reopens comment period for BHT and launches post-market chemical safety program

May 12, 2026·read at fda press ↗RegulatoryNeutral

The U.S. Food and Drug Administration announced two actions as part of its ongoing food chemical safety agenda.

The agency will reopen the comment period for the Request for Information on butylated hydroxytoluene (BHT) in human food and as a food contact substance, extending the deadline by 30 days. Stakeholders can submit electronic comments via Regulations.gov using docket number FDA-2026-N-2526, or send written comments to the Dockets Management Staff in Rockville, MD.

FDA is not reopening the comment period for azodicarbonamide (ADA) because it received no requests for additional time. At the same time, the FDA finalized a new proactive post-market assessment program and began reassessments of both BHT and ADA.

source

This writeup was produced by pharmadog from original reporting by fda press.

Original headline: “FDA Finalizes Food Chemical Safety Post-Market Assessment Program, Launches Reassessment of BHT, ADA”

read at fda press ↗
760 words · retrieved Jul 29
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
Boundless Bio, Inc.2
topics
Vaccines

related stories

  • 5d agoNigeria identifies travel-related Ebola caseSTAT
  • 5d agoA counterintuitive way to build trust in measles vaccines and public healthSTAT
  • Oct 14FDA Launches the Rare Disease Framework Initiative to Develop a Holistic, Fit-For-Purpose Framework for Rare Disease Drug Developmentfda press
  • Oct 9How Abogen went from COVID hype to a $7.8B Novartis dealBioSpace
  • Oct 6Opinion: Why the FDA should not approve an ineffective multicancer screening testSTAT